Literature DB >> 34795405

Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test.

Asher Mullard.   

Abstract

Entities:  

Year:  2022        PMID： 34795405     DOI： 10.1038/d41573-021-00195-4

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization.

Authors:  Yoshifumi Kusumoto; Kyohei Hayashi; Soichiro Sato; Toru Yamada; Iori Kozono; Zenzaburo Nakata; Naoya Asada; Shungo Mitsuki; Ayahisa Watanabe; Chiaki Wakasa-Morimoto; Kentaro Uemura; Shuhei Arita; Shinobu Miki; Tohru Mizutare; Hidenori Mikamiyama
Journal:  ACS Med Chem Lett       Date:  2022-09-01       Impact factor: 4.632

Review 2.  Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.

Authors:  Lauren J Hassen; Steven R Scarfone; Michael Wesley Milks
Journal:  Geriatrics (Basel)       Date:  2022-03-25

Review 3.  Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk.

Authors:  Rishi Rikhi; Michael D Shapiro
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.